Baylor uses Carestream molecular imaging technology
Baylor College of Medicine (BCM) is using the latest optical molecular imaging technology from Carestream Molecular Imaging as part of its research efforts involving cancer, cardiovascular disease, infectious agents, inflammatory disease and other conditions.
The company's Kodak In-Vivo Multispectral Imaging System FX is installed at BCM's Frensley Center for Imaging Research, which uses imaging to support development of novel agents and other research tools used in the detection and treatment of diseases. Researchers apply the system to a wide variety of imaging techniques that combine optical and x-ray, as well as to the development of isotopes for PET and SPECT imaging.
"The Kodak Multispectral System combines optical, x-ray and nuclear imaging, allowing us to more precisely localize the molecular signals in vivo-based on the co-registered multi-imaging modalities," said Shi Ke, MD, technical director of the Frensley Center for Imaging Research, Baylor College of Medicine. "I believe optical molecular imaging has a bright future, because it will offer more target-specific agents in the light spectrum with better accuracy and specificity for disease detection than current PET metabolic agents."
The company's Kodak In-Vivo Multispectral Imaging System FX is installed at BCM's Frensley Center for Imaging Research, which uses imaging to support development of novel agents and other research tools used in the detection and treatment of diseases. Researchers apply the system to a wide variety of imaging techniques that combine optical and x-ray, as well as to the development of isotopes for PET and SPECT imaging.
"The Kodak Multispectral System combines optical, x-ray and nuclear imaging, allowing us to more precisely localize the molecular signals in vivo-based on the co-registered multi-imaging modalities," said Shi Ke, MD, technical director of the Frensley Center for Imaging Research, Baylor College of Medicine. "I believe optical molecular imaging has a bright future, because it will offer more target-specific agents in the light spectrum with better accuracy and specificity for disease detection than current PET metabolic agents."